Hypotrichosis is a term used to describe inadequate or not enough hair growth, and this can be applied to a variety of situations. For example, some people with low levels of thyroid hormones find that their hair thins and does not return to normal when they start using thyroxine to treat their thyroid. The treatment has also been proven to speed up the return of eyelashes and eyebrows after loss from chemotherapy.
The most common use of the treatment is to cosmetically enhance eyelashes by increasing the length and thickness of them. Latisse comes as a solution contained within a smaller dropper bottle with disposable applicators. Allergan is the manufacturer of the treatment which gained United States Federal Drugs Association (FDA) approval in 2008 and it is only available in America.
To gain FDA approval bimatoprost had to undergo studies into its safety and efficacy for this cosmetic application. It was found to be safe and effective at growing eyelashes. The average result was a 25% increase in length, 106% increase in thickness and 18% darker lashes.
Latisse is a registered trademark of Allergan Inc.
Mylash was originally founded by Tom Walker in 2007 based on his knowledge that a well studied treatment for glaucoma, an eye condition, had an interesting side effect – eyelash growth!
He has a keen interest in hair growth and non-surgical ways to improve this for cosmetic purposes and post-chemotherapy.
Dr Walker has been published in the Journal of Plastic and Reconstructive Surgery and has contributed his professional opinions to articles in Hello magazine, Elle, Grazia and many more.
Mylash continues to only use British based medical doctors to ensure a safe service that offers you clinically proven treatments.
Read testimonials from some of our celebrity clients and leading journalists.
Our service has been featured in articles in many major press publications.
Read articles on the science behind the treatment and the latest developments.